Rampart DL Matrix is a dehydrated, dual-layer human amniotic membrane allograft used as a protective biologic barrier over partial- and full-thickness acute and chronic wounds. For the companion product in this portfolio, see the AmnioAMP product overview. The name reflects its defining structural feature: the "DL" stands for dual layer, meaning each unit consists of two sheets of amniotic tissue rather than one. Like other dehydrated amniotic membrane products, Rampart is processed to preserve the collagen-rich extracellular matrix (ECM) and the native growth factors and cytokines associated with tissue repair, and it is applied as a wound covering after debridement and wound-bed preparation. Rampart carries HCPCS code Q4347 and is a recognized option in wound centers and podiatry practices for wounds that have stalled under standard care (PMID 32580594).
What Rampart DL Matrix is made of
The starting material for Rampart is human amniotic membrane, recovered from donated placental tissue during planned cesarean deliveries. Donors are screened and tested under regulated tissue-banking protocols. The membrane is then processed through controlled dehydration, which removes moisture and eliminates viable cells while leaving the ECM architecture and its associated signaling molecules intact. The preserved structural proteins include collagen types I, III, IV, and V, along with fibronectin, laminin, and hyaluronic acid. The processing is designed to retain the matrix-bound growth factors and cytokines that underlie the membrane's biological activity, including transforming growth factor-beta (TGF-β), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) (PMID 32580594).
Because Rampart is dehydrated, it does not contain living or viable cells. The dehydration process eliminates cellular material while preserving the ECM scaffold and the reservoir of signaling molecules bound to it. Current research indicates that the wound-healing activity of dehydrated amniotic membrane allografts derives from these preserved matrix-bound molecules and the structural scaffold they provide, rather than from any cellular viability (PMID 32580594).
Product specifications at a glance
| Attribute | Rampart DL Matrix |
|---|---|
| Product type | Dehydrated dual-layer human amniotic membrane allograft (wound matrix) |
| Source tissue | Human placental amnion |
| Layer count | Dual layer (two sheets of amniotic tissue) |
| Orientation | Non-side specific (either surface may contact the wound bed) |
| Storage | Room temperature (ambient); no freezer or cold chain required |
| HCPCS code | Q4347 (Rampart DL matrix, per square centimeter) |
| CPT application codes | 15271–15278 |
| Cellular viability | Acellular; no viable cells after dehydration |
| Regulatory category | Human cells, tissues, and cellular and tissue-based products (HCT/P) under 21 CFR 1271, Section 361 of the PHS Act |
| Rehydration | Approximately 2–3 minutes in sterile saline per manufacturer Instructions for Use |
How Rampart DL Matrix works in wound healing
Amniotic membrane has been used in wound care and ophthalmology for over a century. Its biological properties relevant to wound healing include structural support, modulation of inflammation, and promotion of re-epithelialization and angiogenesis (PMID 26764358). When applied to a prepared wound bed, a dehydrated amniotic membrane allograft like Rampart provides:
- A biologic barrier. The membrane forms a protective covering over the wound that helps preserve tissue structure and protect the wound bed from mechanical disruption and contamination.
- An ECM scaffold. The collagen-rich matrix provides a structural template that supports cell migration, granulation, and re-epithelialization.
- Matrix-bound growth factors. Preserved signaling molecules — including TGF-β, EGF, VEGF, and PDGF — are associated with angiogenesis, keratinocyte migration, and extracellular matrix remodeling (PMID 32580594).
- Anti-inflammatory signaling. Amniotic membrane has documented anti-inflammatory properties that may help shift a stalled, chronically inflamed wound toward a productive healing trajectory (PMID 26764358).
The dual-layer construction distinguishes Rampart from single-layer dehydrated amniotic membrane products. The two sheets of tissue add mechanical strength during handling and application, which can be an advantage for larger wounds or settings where the graft is manipulated during placement. Recent research on multi-layer amniotic membrane constructs has demonstrated that layer architecture influences the protein profile and mechanical properties of the dressing, supporting the rationale for purpose-built multi-layer designs (PMID 41873642).
Clinical applications and indications
Rampart DL Matrix is indicated as a protective biologic barrier over full-thickness wounds. Common clinical applications in wound care settings include:
- Diabetic foot ulcers (DFUs) — as an adjunct after standard care (offloading, debridement, moisture balance, infection control) has failed to produce adequate healing. A systematic review and meta-analysis found that human amniotic membrane products increased the likelihood of DFU healing compared with standard care alone (PMID 36104736).
- Venous leg ulcers (VLUs) — for recalcitrant ulcers where compression therapy and standard dressings have stalled.
- Pressure injuries — for Stage II–IV injuries needing a biologic barrier and scaffold.
- Burns — as a temporary biological dressing that reduces pain and supports re-epithelialization.
- Surgical and traumatic wounds — for wound dehiscence, skin-graft donor sites, and complex soft-tissue defects.
The broader evidence base for dehydrated amniotic membrane in chronic wounds has continued to strengthen. A 2024 randomized controlled trial demonstrated that dehydrated amnion chorion membrane improved DFU healing rates versus standard of care (PMID 38973638), and 2025 interim results from randomized trials of dehydrated human amnion–intermediate layer–chorion membrane reported favorable outcomes for non-healing DFUs (PMID 41458871). These trials evaluate the dehydrated membrane class rather than Rampart specifically; no published head-to-head trial compares Rampart to a single-layer competitor by brand.
Storage and handling
Rampart DL Matrix is a dehydrated, room-temperature-stored product. This is a practical differentiator from cryopreserved amniotic membrane products, which require frozen storage (−80°C or below), cold-chain shipping, and controlled thawing at the point of care. Ambient storage simplifies inventory management, reduces waste from cold-chain failures, and allows the product to be stocked on a standard shelf in the wound center or procedure room. A study comparing lyopreserved (ambient-stored) and cryopreserved amniotic membrane found that the ambient-stored format offered comparable biological properties with the convenience of room-temperature storage (PMID 30278042). Before application, the dehydrated membrane is rehydrated in sterile saline for approximately 2–3 minutes per the manufacturer's Instructions for Use.
HCPCS billing and coding
Rampart DL Matrix is billed under HCPCS code Q4347 (Rampart DL matrix, per square centimeter) within the CMS skin-substitute billing framework. The application procedure is coded using CPT 15271–15278, which are anatomic- and size-specific codes for the application of a skin substitute graft. Key coding points for wound centers and billing staff:
- Q4347 is a product-specific Q-code; do not substitute a generic amniotic membrane code.
- Document the product name, lot number, size applied (in square centimeters), wound location, and clinical indication for every application.
- Coverage and prior-authorization requirements vary by payer and Medicare Administrative Contractor (MAC). Always verify the current Local Coverage Determination (LCD) for skin substitutes before submitting claims.
- For a full coding and reimbursement walkthrough, see our 2026 reimbursement and coding guide for amniotic membrane allografts.
How Rampart DL Matrix compares to AmnioAMP
NextGen Biologics offers two dehydrated amniotic membrane wound products: AmnioAMP and Rampart DL Matrix. Both are dehydrated, room-temperature-stored human amniotic membrane allografts — neither is cryopreserved. The principal differences are layer count and orientation:
| Attribute | Rampart DL Matrix | AmnioAMP |
|---|---|---|
| Layer count | Dual-layer membrane | Single-layer membrane |
| Orientation | Non-side specific (either side) | Side-specific (stromal side to wound bed) |
| HCPCS code | Q4347 | Q4250 |
| Storage | Room temperature | Room temperature |
| Rehydration | 2–3 min in sterile saline | 2–3 min in sterile saline |
| Format | Dual-layer sheet | Membrane sheet / micronized (MP) |
Rampart's dual-layer construction adds mechanical bulk and handling strength, and its non-side-specific orientation eliminates the risk of placing the wrong surface against the wound bed. AmnioAMP's single layer conforms more easily to irregular surfaces. No published head-to-head clinical trial directly compares these two branded products. For a detailed side-by-side comparison, see our AmnioAMP vs Rampart comparison guide.
Application protocol summary
Rampart application follows standard biologic graft protocol: wound-bed preparation, debridement of nonviable tissue, infection control, hemostasis, rehydration of the graft, trimming to wound margins, placement, and dressing. Because Rampart is non-side specific, either surface may be placed against the wound bed. For a complete step-by-step team protocol, see our Rampart clinical guide for wound care teams.
Frequently asked questions
What is Rampart DL Matrix?
Rampart DL Matrix is a dehydrated, dual-layer human amniotic membrane allograft used as a protective biologic barrier over acute and chronic wounds. The "DL" stands for dual layer. It is stored at room temperature and carries HCPCS code Q4347. It is indicated for diabetic foot ulcers, venous leg ulcers, pressure injuries, surgical wounds, and burns.
What is Rampart wound matrix made of?
Rampart is made from human amniotic membrane recovered from donated placental tissue. The membrane is dehydrated, leaving a collagen-rich extracellular matrix that retains native growth factors and cytokines including TGF-β, EGF, VEGF, and PDGF. Each unit contains two layers of this tissue. It does not contain living cells after dehydration.
What HCPCS code is used for Rampart DL Matrix?
Rampart is billed under HCPCS code Q4347 (Rampart DL matrix, per square centimeter) under the CMS skin-substitute billing framework. The CPT application codes 15271–15278 apply to the application procedure. Coverage varies by payer and MAC; always verify the current LCD before submitting claims.
Is Rampart cryopreserved or dehydrated?
Rampart is a dehydrated amniotic membrane product, not cryopreserved. It is stored at room temperature and does not require frozen storage, cold-chain logistics, or controlled thawing. Some amniotic membrane products on the market are cryopreserved, but Rampart is a dehydrated format.
How is Rampart DL Matrix stored?
Rampart is a dehydrated product stored at room temperature. It does not require a freezer, cryopreservation, or cold-chain logistics. Ambient storage simplifies inventory management and reduces waste from cold-chain failures.
What wounds is Rampart used for?
Rampart is indicated as a protective biologic barrier over full-thickness wounds: diabetic foot ulcers, venous leg ulcers, pressure injuries, surgical wounds, and burns. It is typically used as an adjunct after standard wound care has stalled.
Is Rampart side-specific or non-side specific?
Rampart DL Matrix is non-side specific — either surface of the membrane can contact the wound bed. This simplifies placement and eliminates the risk of orienting the wrong surface against the wound bed. Single-layer side-specific products require the stromal or basement-membrane side to face the wound bed.
How is Rampart DL Matrix applied?
Rampart is applied after wound-bed preparation and debridement. The dehydrated membrane is rehydrated in sterile saline for approximately 2–3 minutes per the Instructions for Use, trimmed to overlap the wound margins by 1–2 mm, placed on the wound bed in either orientation (non-side specific), and secured with a non-adherent primary dressing and an appropriate secondary layer based on exudate level. Offloading or pressure redistribution is important for lower-extremity wounds.
Key takeaways:
- Rampart DL Matrix is a dehydrated, dual-layer human amniotic membrane allograft — not cryopreserved.
- It is stored at room temperature and rehydrated in sterile saline (2–3 minutes) before application.
- HCPCS code Q4347 applies; CPT 15271–15278 covers the application procedure.
- It is non-side specific, simplifying placement — either surface may contact the wound bed.
- The dual-layer construction adds mechanical strength during handling and application.
- Clinical applications include DFUs, VLUs, pressure injuries, burns, and post-surgical wounds.
Ready to evaluate Rampart or AmnioAMP in your wound center? Request samples or a clinical-affairs consultation.
References
- Joshi CJ, et al. Up-to-date role of the dehydrated human amnion/chorion membrane (AMNIOFIX) for wound healing. Expert Opin Biol Ther. 2020. PMID 32580594. https://pubmed.ncbi.nlm.nih.gov/32580594/
- Mohammed YA, et al. Human amniotic membrane products for patients with diabetic foot ulcers: do they help? A systematic review and meta-analysis. J Foot Ankle Res. 2022. PMID 36104736. https://pubmed.ncbi.nlm.nih.gov/36104736/
- Ilic D, et al. Human amniotic membrane grafts in therapy of chronic non-healing wounds. Br Med Bull. 2016. PMID 26764358. https://pubmed.ncbi.nlm.nih.gov/26764358/
- Cazzell SM, et al. Dehydrated Amnion Chorion Membrane versus standard of care for diabetic foot ulcers: a randomised controlled trial. J Wound Care. 2024. PMID 38973638. https://pubmed.ncbi.nlm.nih.gov/38973638/
- Hall HJ, et al. Bridging the Wound Gap: Interim Results From Randomized Trials Evaluating Dehydrated Human Amnion-Intermediate Layer-Chorion Membrane for the Treatment of Non-healing Diabetic Foot Ulcers. Cureus. 2025. PMID 41458871. https://pubmed.ncbi.nlm.nih.gov/41458871/
- Dhall S, et al. Properties of viable lyopreserved amnion are equivalent to viable cryopreserved amnion with the convenience of ambient storage. PLoS One. 2018. PMID 30278042. https://pubmed.ncbi.nlm.nih.gov/30278042/
- Safavieh M, et al. A Triple-Layer Amniotic Membrane Dressing Drives Robust Wound Healing: In-Depth Protein Profiling and In Vivo Validation in Rat and Human Subjects. ACS Appl Bio Mater. 2026. PMID 41873642. https://pubmed.ncbi.nlm.nih.gov/41873642/
This overview is provided for clinician education and product evaluation. Rampart and AmnioAMP are human tissue products regulated under 21 CFR 1271. Product-specific labeling, Instructions for Use, and the current Medicare Administrative Contractor Local Coverage Determination govern clinical use and billing. Always follow the manufacturer's Instructions for Use and institutional protocols.